At the time of the present study’s initiation, planning was underway for BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) (Slamon et al. 2013), a large phase III adjuvant study in which patients with HER2-positive breast cancer were randomly assigned to receive docetaxel, carboplatin, and trastuzumab (TCH) with or without bevacizumab. The gene discussed is ERBB2; the disease is breast carcinoma.